IPM clocks Rs 8446 crores in April 2016

12 therapies have outgrown the IPM growth

The Indian Pharma Market (IPM) has clocked Rs 8446 crores in April 2016 and has grown at 3.5 per cent. Amongst the top 10, Mankind grew at 12.3 per cent, Abbott at 9.9 per cent followed by Macleods at 5.8 per cent. 21 corporates have crossed the growth of IPM amongst top 50. Amongst the top 50 corporates, Bharat Serum has the highest growth of 25.2 per cent followed by Systopic at 18.3 per cent and Eris at 15.6 per cent.

10 corporates have shown growths of more than 10 per cent amongst the top 50.  Amongst the 11-20 ranked corporates, Intas has the highest growth of 10.8 per cent followed by Micro at 8.6 per cent and USV at 5.1 per cent. Amongst the 21-30 ranked corporates, Eris has the highest growth at 15.6 per cent followed by Novartis at 12.1 per cent and Wockhardt at 4.8 per cent. Amongst the 31-40 ranked corporates, Bharat Serums grew at 25.2 per cent followed by Akumentis at 11.8 per cent and Wallace at 11 per cent. Amongst the 41-50 ranked corporates, Systopic has the highest growth at 18.3 per cent followed by Janssen at 15.3 per cent and Win-Medicare at 12.3 per cent. Amongst the 51-60 ranked corporates, Boehringer grew at 58.7 per cent followed by Fresenius Kabi at 29.2 per cent and Corona at 19 per cent.  Amongst the 61-70 ranked corporates, Shreya grew at 37.8 per cent followed by RPG at 15.7 per cent  and East India at 7.8 per cent. Amongst the 71-80 ranked corporates, Samarth grew at 38 per cent followed by Danone at 20.8 per cent and Lincoln at 11.2 per cent. Amongst the 81 -90 ranked corporates, Dabur grew at 61.7 per cent followed by Veritaz grew at 30.5 per cent followed by Galderma at 17.6 per cent. Amongst the 91- 100 ranked corporates, Ind-Swift grew at 67.2 per cent followed by Sanzyme at 30.8 per cent and Curatio at 27 per cent. The 100th biggest corporate is Curatio and 150th biggest corporate is UTH in the IPM.

Abbott HC grew at 9.8 per cent whereas Abbott India grew at 10.8 per cent. Zuventus crossed Rs 1000-crore on MAT Basis to be at Rs 1006-crores as per April MAT 2016.

Indian companies have grown at 3.6 per cent versus 3.4 per cent for MNCs in April 2016. Amongst the top 50 in MNCs, Janssen grew at 15.3 per cent followed by Novartis at 12.1per cent and Abbott at 9.9 per cent. Under the non-NLEM category, Indian companies grew at 4.6 per cent whereas MNCs grew at 3.3 per cent.

The NLEM 2013 containing molecules market grew at -2.7 per cent whereas the non-DPCO market grew by 4.3 resulting in an overall growth of 3.5 per cent for April 2016. The NLEM and Non-NLEM category showed unit growth of -3.2 per cent and -6.5 per cent respectively.

From therapy perspective, 12 therapies have outgrown the IPM growth. The respiratory market grew at -6 per cent, gastrointestinal market grew at 5 per cent, pain and analgesics market grew at 0.7 per cent whereas anti – infectives grew at -3.5 per cent. The anti – diabetic market grew at 12.1 per cent and cardiac at 7.4 per cent, neuro/ CNS at 9 per cent in chronic business. The anti – malarials grew at -14.7 per cent and the derma market grew by 7.1 per cent followed by the urology market at 10.4 per cent.

From the regional perspective, 17 regions have outgrown the IPM growth. The Punjab market grew the highest at 12.9 per cent followed by Haryana market at 9.1 per cent and Saurashtra market at nine per cent. Eight regions had negative growth in April 2016. The Amoxycillin + Clavulanic acid  market grew at -4.9 per cent and Glimepiride + Metformin market  grew at 10.6 per cent. The markets of paracetamol grew at 12.1 per cent, Atorvastatin 0.7 per cent, Probiotic Microbes at 25.6 per cent, Cefixime at -8.1 per cent, Pantoprazole at 8.5 per cent, Montelukast + Levocetrizine at -1.7 per cent, Glimepiride + Metformin + Pioglitazone at -19.2 per cent, Vitamin-D at 15.2 per cent, Hydroquinone + Mometasone + Tretinoin at -1.3 per cent, Voglibose + Metformin + Glimepiride at 32.6 per cent, Rosuvastatin at 12.2 per cent, protein supplements at 5.8 per cent, Azithromycin at -10.1 per cent, Calcium Carbonate + Vit D3 market at -5.8 per cent, Paracetamol + Phenylephrine + Chlorpheniramine at -16.7 per cent, Meropenem at 37.2 per cent, Montelukast + Fexofenadine at 5.6 per cent, Diclofenac at 13.3 per cent, Telmisartan at 3.3 per cent, Levetiracetam at 20.5 per cent.  The 50th biggest market is Voglibose + Metformin + Glimepiride and the 100th biggest market is Levofloxacin for April 2016. Mixtard leads the pack with Rs 36 crores followed by Glycomet GP at Rs 31 crores, Corex at Rs 28 crores and Augmentin at Rs 23 crores for April 2016.

Few brands which have gained ranks include Revital H (+2399), Meronem (+94), Rotarix (+73), Trajenta (+59), Januvia (+41), Rabipur (+36), Minipress XL (+34), Ultracet (+30), Udiliv, Novomix (+27), Unwanted Kit (+26), Galvus (+21), Rosuvas, Mikacin, Vertin, Aciloc RD (+20), Telma H (+19), Electral Powder (+18), Cardace (+16), Duphaston (+15), Galvus Met (+14), Istamet (+13), Atorva, Mucaine (+12), Pan D, Allegra (+11), Levipil (+10), Synflorix, Jalra M (+9), Lantus, Volini (+8), Betadine, Pan, Gemer (+7), Voveran, Susten (+6), Corex, Rantac, Thyronorm, Pantop (+5), Clapol, Clexane (+4), Zoryl M (+3), Dolo (+2) amongst top 100 Brands over April 2015.

Lonopin, Lobate GM, Razo D, Sporlac, Zerodol P, Candid, Mero, Acitrom, Metpure XL, Prega News, Telma AM, Cilacar, Enterogermina are few brands which have gained ranks in 101-200 ranked brands.

A few of the brands that have moved up ranks fastest into Top 300 brands for April 2016 are Revital H, Hucog HP, Imicrit, Similac, Lonopin, Candiforce, Lobate GM, Orofer FCM, Razo D, Looz. The 300th biggest Brand is Pentaxim  from Sanofi

A total of 306 brands and 489 SKUs were launched in April 2016. The top new brands for April 2016 were Vivitra, Insta and Lomofen Plus. Three brands were launched each in Teneligliptin Plain and in Combination with Metformin. Sanofi launched Gemigliptin under the brand name Zemiglo. Within the VMS category, Jubinerv (Jubilant), PartySafe (Obsurge), Escor Z (Adroit) were launched followed by Glyciphage VG (Franco), Tiban M (Ajanta) & Teneliglip (Akumentis) in anti-diabetic, Itratuf (Alkem), Kromalite (FDC) & Kezolin (FDC) in derma, Ovalife Met (Macleods) and Mychiro (USV) in gynaec, Ostivestin, Candivestin (Zydus), Dologesic SP (Micro) in pain and analgesics category, Airlung FX (Zydus), Kofirax ( Hetero), Newcold ML (Abbott) in respiratory, Rozagold (Sun), Telmurix (Akesiss) & Roseday Gold (USV) in cardiac and Novogermina (Alkem), Acidart (Juggat), Fosaprepit ( Cipla) in gastro intestinal segment.

The biggest new launch by a MNC is Zemiglo from Sanofi in April 2016.

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used

MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit http://www.aiocdawacs.com